* TherapeuticsMD Inc. submitted a new drug application to the U.S. Food and Drug Administration for TX-001HR, a treatment for menopause-related symptoms known as hot flashes. The treatment is a bio-identical hormone therapy combination of estradiol and progesterone.
* Immunicum AB (publ) completed its 90% secured rights issue with preferential rights for existing shareholders, generating proceeds of about 168 million Swedish kronor after transaction costs. The money raised will enable the company to conclude its phase 2 Mereca and phase 1/2 Gist clinical trials for cancer treatment ilixadencel.
M&A and capital markets
* Israel-based BioCancell Ltd.'s shareholders turned down a tender offer to take the company private, Reuters reported.
* Chugai Pharmaceutical Co. Ltd. is planning to invest about ¥25 billion in a Singapore research laboratory for biopharmaceuticals by 2021, looking to expand the development of therapeutic antibodies, Nikkei Asian Review reported. The lab will seek to make antibodies more functional.
* FierceBiotech has a feature about the possibility of using chimeric antigen receptor T cells, or CAR-T cell therapy, for treating HIV. CAR-T cell therapies have been approved in the U.S. this year to treat specific cancers.
* Side effects might outweigh the positive results for Johnson & Johnson's depression treatment esketamine, Endpoints News reports. The treatment was shown to improve patients' MADRS scores, a measure of the severity of depressive episodes, but caused side effects including perceptual changes and dissociative symptoms.
The Daily Dose is updated as of 6:30 a.m. ET. Some external links may require a subscription.